Longevity network
Longevity Centers of America (Netzwerk)
- Hormone therapy (HRT / BHRT)
- Peptide therapy
§ — Substance profile
TP-7 · Synthetic tuftsin analogue
01 — Regulatory status
Regulatory status · United States · as of September 2026
Not FDA-approved. Not on the 503A Bulks List. Status against the current FDA list must be verified before publication.
Source: FDA 503A Bulks List · PCAC meeting records · verified September 2026
Reviewed September 2026 · Sources: FDA, EMA
02 — Researched for
Generalized anxiety disorder, cognitive function under stress.
03 — What the evidence shows
Small Russian trials compare it to benzodiazepines in anxiety with reported non-inferiority; methodology and independence are limited. No Western trial.
04 — What is claimed but not shown
Nootropic effect in healthy adults; immune modulation with clinical relevance.
05 — Known risks
Sparse safety reporting; nasal administration effects; unregulated sourcing.
06 — Researched for these goals
Related substances
07 — Questions for your physician
Listing in the registry is not an endorsement of any substance or protocol, and it is not a statement that a treatment is approved.
Reviewed September 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.